A number of research firms have changed their ratings and price targets for AmerisourceBergen Corporation (Holding Co) (NYSE: ABC):

  • 8/7/2017 – AmerisourceBergen Corporation (Holding Co) was given a new $90.00 price target on by analysts at Leerink Swann. They now have a “buy” rating on the stock.
  • 8/5/2017 – AmerisourceBergen Corporation (Holding Co) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/4/2017 – AmerisourceBergen Corporation (Holding Co) had its price target lowered by analysts at UBS AG from $94.00 to $87.00. They now have a “neutral” rating on the stock.
  • 8/4/2017 – AmerisourceBergen Corporation (Holding Co) was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “AmerisourceBergen had an unimpressive run on the bourse over the last one month, trading below the broader industry in terms of price performance. The company faces headwinds due to the slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics. Furthermore, a temporary slowdown in PharMEDium's growth is expected to mar the company’s bottom line. AmerisourceBergen expects a moderation in growth in fiscal 2017 due to a challenging healthcare landscape, as both healthcare providers and pharmaceutical manufacturers are facing increasing cost pressures. The company operates in a highly competitive pharmaceutical distribution and related health care space. Furthermore, the generic industry is facing consolidation of customers and manufacturers, globalization and increasing quality and regulatory challenges. Added to this, AmerisourceBergen’s expensive valuation multiples pose risk owing to Trump’s unclear policy towards brand pricing.”
  • 8/3/2017 – AmerisourceBergen Corporation (Holding Co) was downgraded by analysts at TheStreet from a “b” rating to a “c+” rating.
  • 7/24/2017 – AmerisourceBergen Corporation (Holding Co) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/13/2017 – AmerisourceBergen Corporation (Holding Co) had its “buy” rating reaffirmed by analysts at Credit Suisse Group. They now have a $95.00 price target on the stock.
  • 7/10/2017 – AmerisourceBergen Corporation (Holding Co) was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “AmerisourceBergen had an unimpressive run on the bourse over the last one month, trading below the broader industry in terms of price performance. The company faces headwinds due to the slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics. Furthermore, a temporary slowdown in PharMEDium's growth is expected to mar the company’s bottom line. AmerisourceBergen expects a moderation in growth in fiscal 2017 due to a challenging healthcare landscape, as both healthcare providers and pharmaceutical manufacturers are facing increasing cost pressures. The company operates in a highly competitive pharmaceutical distribution and related health care space. Furthermore, the generic industry is facing consolidation of customers and manufacturers, globalization and increasing quality and regulatory challenges. Added to this, AmerisourceBergen’s expensive valuation multiples pose risk owing to Trump’s unclear policy towards brand pricing.”
  • 6/30/2017 – AmerisourceBergen Corporation (Holding Co) was downgraded by analysts at Bank of America Corporation from a “buy” rating to a “neutral” rating. They now have a $94.00 price target on the stock, down previously from $95.76.
  • 6/21/2017 – AmerisourceBergen Corporation (Holding Co) had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $95.00 price target on the stock.
  • 6/17/2017 – AmerisourceBergen Corporation (Holding Co) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.

Shares of AmerisourceBergen Corporation (NYSE ABC) traded down 1.15% during trading on Thursday, hitting $78.88. 2,417,110 shares of the stock traded hands. AmerisourceBergen Corporation has a 1-year low of $68.38 and a 1-year high of $97.85. The firm has a market capitalization of $17.28 billion, a price-to-earnings ratio of 20.55 and a beta of 0.91. The firm has a 50-day moving average of $91.85 and a 200-day moving average of $89.29.

AmerisourceBergen Corporation (Holding Co) (NYSE:ABC) last announced its earnings results on Thursday, August 3rd. The company reported $1.43 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.06. AmerisourceBergen Corporation (Holding Co) had a net margin of 0.56% and a return on equity of 56.07%. The business had revenue of $38.71 billion during the quarter, compared to the consensus estimate of $39.13 billion. During the same quarter last year, the firm earned $1.37 earnings per share. AmerisourceBergen Corporation (Holding Co)’s quarterly revenue was up 4.9% on a year-over-year basis. On average, equities analysts forecast that AmerisourceBergen Corporation will post $5.88 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 5th. Investors of record on Monday, August 21st will be paid a dividend of $0.365 per share. This represents a $1.46 dividend on an annualized basis and a yield of 1.85%. AmerisourceBergen Corporation (Holding Co)’s dividend payout ratio is presently 38.02%.

In related news, Chairman Steven H. Collis sold 15,000 shares of AmerisourceBergen Corporation (Holding Co) stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $91.73, for a total transaction of $1,375,950.00. Following the completion of the transaction, the chairman now owns 253,876 shares of the company’s stock, valued at $23,288,045.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 27.40% of the stock is owned by company insiders.

AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company’s segments include Pharmaceutical Distribution and Other. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers.

Receive News & Ratings for AmerisourceBergen Corporation (Holding Co) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen Corporation (Holding Co) and related companies with Analyst Ratings Network's FREE daily email newsletter.